← Back to All Filings

Celularity Inc. Director Granted 30,000 Restricted Stock Units (RSUs)

Low SignificanceJanuary 15, 2026 at 4:35:46 PM EST

Celularity Inc

$CELU4/ACIK: 0001752828

Subscribe to track CELU

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Celularity Inc. Director Granted 30,000 RSUs

Company: Celularity Inc (CELU) Form: 4/A | Filed: 2026-01-15 Significance: Low

Insider: Parks Diane L. Title: null | Relationship: Director

Transaction: • Type: Grant • Shares: 30,000 RSUs • Price: $0.00 • Value: $0 • Owned After: 520,021

Key Insight: This is a routine grant of Restricted Stock Units (RSUs) to a director as part of their compensation, intended to align their interests with shareholders.

Market Context: For a company with a $40 million market cap, such equity compensation is a standard practice and is not considered a significant market signal.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: Celularity Inc (CELU)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: A director received a routine grant of 30,000 Restricted Stock Units (RSUs) as part of their compensation package.
  • Market Impact: Neutral. This is a standard corporate governance action and not a direct market signal.

Company Information

FieldValue
CompanyCelularity Inc
Ticker SymbolCELU
CIK0001752828
IndustryPHARMACEUTICAL PREPARATIONS

Insider Information

FieldValue
NameParks Diane L.
CIK0001781026
Title/Positionnull
RelationshipDirector

Transaction Details

FieldValue
Form Type4/A
Transaction Date2026-01-12
Transaction CodeA (Award)
Security TypeClass A Common Stock (as RSUs)
Shares Involved30,000
Price Per Share$0.00
Total Value$0
Shares Owned After520,021
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$0
% of Market Cap0.0%
Shares Transacted30,000
% of Shares OutstandingData Not Available
Post-Transaction Ownership520,021 shares
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: The company has a market capitalization of approximately $40 million. The grant has a transaction value of $0, making its immediate financial impact negligible as a percentage of market cap.
  • Ownership Concentration: The director now holds 520,021 shares. Without shares outstanding data, the exact ownership percentage cannot be determined.
  • Dilution Impact: The issuance of 30,000 new shares upon vesting will cause minor dilution to existing shareholders. The exact percentage impact cannot be calculated without the total shares outstanding figure.
  • Transaction Significance: The transaction is an equity award, a common form of non-cash compensation for directors. It is not an open-market purchase and carries low significance as a trading signal.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: Equity grants to directors are routine and expected forms of compensation. They do not signal new information about the company's immediate prospects.

Volume & Sentiment

  • Expected Volume Impact: None. This is not an open-market transaction and will not directly affect trading volume.
  • Sentiment Indicator: Neutral. The market generally views such compensation as a standard cost of doing business.

Additional Context

Transaction Notes

  • Special Circumstances: The filing notes these are Restricted Stock Units (RSUs) granted under the company's 2021 Equity Incentive Plan. The RSUs vested immediately upon grant.
Topics:#SECFiling#InsiderTransaction#CELU#Celularity#Form4#RSUgrant#CorporateGovernance#StockMarket#Investing

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.